Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records

Introduction Schizophrenia is a chronic neuropsychiatric disorder which affects over 20 million people worldwide. Atypical antipsychotics are the first-line choice for the treatment of schizophrenia due to improved tolerability and diminished risk of extrapyramidal symptoms. Lurasidone is an atypic...

Full description

Bibliographic Details
Main Authors: C. De La Pinta, I. Gabarda
Format: Article
Language:English
Published: Cambridge University Press 2022-06-01
Series:European Psychiatry
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S0924933822005442/type/journal_article
_version_ 1797617431620878336
author C. De La Pinta
I. Gabarda
author_facet C. De La Pinta
I. Gabarda
author_sort C. De La Pinta
collection DOAJ
description Introduction Schizophrenia is a chronic neuropsychiatric disorder which affects over 20 million people worldwide. Atypical antipsychotics are the first-line choice for the treatment of schizophrenia due to improved tolerability and diminished risk of extrapyramidal symptoms. Lurasidone is an atypical antipsychotic approved in Spain for the treatment of schizophrenia in September 2019. An RWD-based picture of lurasidone use is necessary to better understand its impact in routine clinical practice. Objectives To set up a methodology based on Natural Language Processing (NLP) and machine learning for the analysis of the free-text information contained in the EHRs of patients treated with lurasidone in Spain. Methods A multicenter, retrospective study based on RWD collected in EHRs of lurasidone users will be conducted in hospitals from the Spanish National Healthcare System. Information extracted from the free text in EHRs using NLP will be treated and analyzed as big data. Results A study database for lurasidone-treated patients in Spain has been instituted using the EHRead® technology ( Figure 1), which applies machine learning and deep learning to extract, analyze, and interpret the free-text information written in their de-identified EHRs. Sociodemographic and clinical variables in EHRs from September 2019 until the most recent data available are being collected to describe the target patient population and address treatment-related outcomes. Conclusions NLP of free text in EHRs of lurasidone-treated patients renders a real-world picture of lurasidone usage in Spain. Studies using artificial intelligence techniques represent a novel source of information regarding psychiatric disorders and their clinical management. Disclosure I. Gabarda is employee at Angelini Pharma España, S.L.U. and C. de la Pinta is employee at Medsavana.
first_indexed 2024-03-11T07:54:50Z
format Article
id doaj.art-a752f9ded4f84daf8c222d8141565e45
institution Directory Open Access Journal
issn 0924-9338
1778-3585
language English
last_indexed 2024-03-11T07:54:50Z
publishDate 2022-06-01
publisher Cambridge University Press
record_format Article
series European Psychiatry
spelling doaj.art-a752f9ded4f84daf8c222d8141565e452023-11-17T05:05:57ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S208S20810.1192/j.eurpsy.2022.544Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health RecordsC. De La Pinta0I. Gabarda1Medsavana, Medcore, Madrid, SpainAngelini Pharma España, S.L.U., Medical Department, Barcelona, Spain Introduction Schizophrenia is a chronic neuropsychiatric disorder which affects over 20 million people worldwide. Atypical antipsychotics are the first-line choice for the treatment of schizophrenia due to improved tolerability and diminished risk of extrapyramidal symptoms. Lurasidone is an atypical antipsychotic approved in Spain for the treatment of schizophrenia in September 2019. An RWD-based picture of lurasidone use is necessary to better understand its impact in routine clinical practice. Objectives To set up a methodology based on Natural Language Processing (NLP) and machine learning for the analysis of the free-text information contained in the EHRs of patients treated with lurasidone in Spain. Methods A multicenter, retrospective study based on RWD collected in EHRs of lurasidone users will be conducted in hospitals from the Spanish National Healthcare System. Information extracted from the free text in EHRs using NLP will be treated and analyzed as big data. Results A study database for lurasidone-treated patients in Spain has been instituted using the EHRead® technology ( Figure 1), which applies machine learning and deep learning to extract, analyze, and interpret the free-text information written in their de-identified EHRs. Sociodemographic and clinical variables in EHRs from September 2019 until the most recent data available are being collected to describe the target patient population and address treatment-related outcomes. Conclusions NLP of free text in EHRs of lurasidone-treated patients renders a real-world picture of lurasidone usage in Spain. Studies using artificial intelligence techniques represent a novel source of information regarding psychiatric disorders and their clinical management. Disclosure I. Gabarda is employee at Angelini Pharma España, S.L.U. and C. de la Pinta is employee at Medsavana. https://www.cambridge.org/core/product/identifier/S0924933822005442/type/journal_articleschizophréniaElectronic Health RecordslurasidoneNatural Language Processing
spellingShingle C. De La Pinta
I. Gabarda
Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
European Psychiatry
schizophrénia
Electronic Health Records
lurasidone
Natural Language Processing
title Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
title_full Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
title_fullStr Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
title_full_unstemmed Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
title_short Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
title_sort clinical characteristics of lurasidone treated patients in spain using natural language processing a real world data study with electronic health records
topic schizophrénia
Electronic Health Records
lurasidone
Natural Language Processing
url https://www.cambridge.org/core/product/identifier/S0924933822005442/type/journal_article
work_keys_str_mv AT cdelapinta clinicalcharacteristicsoflurasidonetreatedpatientsinspainusingnaturallanguageprocessingarealworlddatastudywithelectronichealthrecords
AT igabarda clinicalcharacteristicsoflurasidonetreatedpatientsinspainusingnaturallanguageprocessingarealworlddatastudywithelectronichealthrecords